Cargando…

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC

Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bansal, Pranshu, Osman, Diaa, Gan, Gregory N., Simon, George R., Boumber, Yanis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854869/ https://www.ncbi.nlm.nih.gov/pubmed/27200298 http://dx.doi.org/10.3389/fonc.2016.00112

Ejemplares similares

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
por: Zer, Alona, et al.
Publicado: (2014)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Malapelle, Umberto, et al.
Publicado: (2021)

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Khaddour, Karam, et al.
Publicado: (2020)

Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
por: Deneka, Alexander Y., et al.
Publicado: (2019)

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
por: Arora, Sanjeevani, et al.
Publicado: (2019)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

NSD1 supports cell growth and regulates autophagy in HPV-negative head and neck squamous cell carcinoma
por: Topchu, Iuliia, et al.
Publicado: (2023)

Bone Invasive Meningioma: Recent Advances and Therapeutic Perspectives
por: Takase, Hajime, et al.
Publicado: (2022)

Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine
por: Graham, Donna M., et al.
Publicado: (2014)

Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling
por: Leong, Tracy L., et al.
Publicado: (2023)

Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma
por: Yanagi, Teruki, et al.
Publicado: (2018)

Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer
por: Vincent, Mark D.
Publicado: (2014)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

LKB1: Can We Target an Hidden Target? Focus on NSCLC
por: Ndembe, Gloriana, et al.
Publicado: (2022)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies
por: Xu, Ruiyuan, et al.
Publicado: (2020)

Recent Advances in Cancer Plasticity: Cellular Mechanisms, Surveillance Strategies, and Therapeutic Optimization
por: Fanelli, Giuseppe Nicolò, et al.
Publicado: (2020)

Ex Vivo Drug Screening Informed Targeted Therapy for Metastatic Parotid Squamous Cell Carcinoma
por: Nykänen, Noora, et al.
Publicado: (2021)

Collagen Kinase Receptors as Potential Therapeutic Targets in Metastatic Colon Cancer
por: Lafitte, Marie, et al.
Publicado: (2020)

Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy
por: Bolte, Fabian J., et al.
Publicado: (2022)

Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma
por: Fuchs, Joseph R., et al.
Publicado: (2023)

Recent advances in the diagnostic and therapeutic roles of microRNAs in colorectal cancer progression and metastasis
por: Liang, Chen, et al.
Publicado: (2022)

INST OX‐05‐024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial
por: Patt, Yehuda Z., et al.
Publicado: (2017)

Liquid Biopsies in Renal Cell Carcinoma—Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease
por: Lakshminarayanan, Harini, et al.
Publicado: (2020)

Systems Biomedicine of Primary and Metastatic Colorectal Cancer Reveals Potential Therapeutic Targets
por: Piran, Mehran, et al.
Publicado: (2021)

Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
por: Melosky, Barbara
Publicado: (2017)

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
por: Liu, Stephen V., et al.
Publicado: (2022)

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study
por: Schneider, Marc A., et al.
Publicado: (2022)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
por: Klinac, Dragana, et al.
Publicado: (2013)

Recent advances in nanomedicine preparative methods and their therapeutic potential for colorectal cancer: a critical review
por: Jain, Arinjay, et al.
Publicado: (2023)

Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
por: Rodriguez-Lara, Vianey, et al.
Publicado: (2023)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
por: Cheng, Xuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3nvlck2isso5rcru9d7k3nf9q7